Nebu~Flow

Founded 2019
Employees 5+
Primary contact
11 The Square
University Avenue
G12 8QQ Glasgow
Scotland
United Kingdom
Diseases & Conditions
Nebuflow, a University of Glasgow medical spin-out, is developing the next generation of nebulisers. Its patented aerosol formation technology allows for the efficient delivery of hard-to-nebulise drugs to the lungs. As such, it is made for both existing formulations and emerging novel high-value therapeutics such as biologics, nanomedicines, and vaccines — enabling medical professionals to cure respiratory diseases.
Founded 2019
Employees 5+
Primary contact
11 The Square
University Avenue
G12 8QQ Glasgow
Scotland
United Kingdom
Diseases & Conditions

Funding πŸ’°

Total Β£2.7M
Select investors Foresight Williams, Ascension, Science Creates Ventures, SIS Ventures, Innovate UK

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • Patented tech: Nebu~Flow is developing its nebuliser platform that enables efficient delivery of a wide range of formulations. It features a short nebulisation time, it's easy to clean, silent, while supporting a wide range of formulations.
  • It works: Nebu~Flow uses surface acoustic wave (SAW) nebulisation technology and has been used successfully to nebulise a range of placebo and commercially available formulation types with a wide range of physical properties, including those with very low surface tension and high viscosity. πŸ”—
  • Big market: Global nebuliser market is valued at more than $1 billion, while the worldwide inhalable drug market is estimated to be worth more than $43 billion in 2022. πŸ”—

Awards & Recognitions πŸ†

  • 2020 Lee Lucas Award
  • 2019 Scottish Edge HIGGS: Winner

Quotes πŸ’¬

Nebu~Flow's development of delivery mechanisms tailored to specific drugs represents an opportunity to expand the market and improve patient outcomes. Foresight Williams Technology's expertise will offer significant value as the company develops its products, and we look forward to working with the team at Nebu-Flow during the next stage of their growth.
Bill Yost, investment manager at Foresight πŸ”—
Last update: April 5, 2023